Teachers Retirement System of The State of Kentucky trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 331,426 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Gilead Sciences were worth $23,459,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. increased its stake in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. BlackRock Inc. increased its stake in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares during the last quarter. Pioneer Investment Management Inc. increased its stake in Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after acquiring an additional 1,595,085 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its stake in Gilead Sciences by 90.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after acquiring an additional 1,229,916 shares during the last quarter. Institutional investors own 76.23% of the company’s stock.

GILD has been the topic of a number of research analyst reports. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank Of Canada began coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price objective on the stock. J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Wells Fargo & Company reiterated a “market perform” rating and set a $81.00 price objective (up from $73.00) on shares of Gilead Sciences in a research report on Thursday, August 31st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $85.22.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.78 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market capitalization of $97,660.00, a P/E ratio of 7.58, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the business posted $2.75 EPS. The business’s revenue was down 13.2% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is presently 23.66%.

In other news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 458,486 shares of company stock valued at $35,190,731. 1.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/01/teachers-retirement-system-of-the-state-of-kentucky-has-23-46-million-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.